COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study

Br J Haematol. 2021 Aug;194(3):646-650. doi: 10.1111/bjh.17526. Epub 2021 May 24.
No abstract available

Keywords: chemotherapy; chronic lymphocytic leukaemia; clinical trial; minimal residual disease; monoclonal antibody.

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bendamustine Hydrochloride / administration & dosage
  • Bendamustine Hydrochloride / therapeutic use
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / therapeutic use
  • Female
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Male
  • Middle Aged
  • Treatment Outcome
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives
  • Vidarabine / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Cyclophosphamide
  • Bendamustine Hydrochloride
  • Vidarabine
  • ofatumumab
  • fludarabine

Associated data

  • ISRCTN/ISRCTN51382468